Top

Published in:

Open Access 09-07-2022 | Obesity | Review

Prophylactic Cefazolin Dosing in Obesity—a Systematic Review

Authors: Matthew Coates, Alison Shield, Gregory M. Peterson, Zahid Hussain

Published in: Obesity Surgery | Issue 9/2022

Abstract

Currently, there is no consensus on whether a standard 2-g prophylactic cefazolin dose provides sufficient antimicrobial coverage in obese surgical patients. This systematic review analysed both outcome and pharmacokinetic studies, aiming to determine the appropriate cefazolin dose. A systematic search was conducted using 4 databases. In total, 3 outcome and 15 pharmacokinetic studies met the inclusion criteria. All 3 outcome studies concluded that there is no need for increased dose. Also, 9 pharmacokinetic studies reached this conclusion; however, 6 pharmacokinetic studies recommended that 2-g dose is insufficient to achieve adequate plasma or tissue concentrations. The stronger body of evidence supports that 2-g dose of cefazolin is sufficient for surgery lasting up to 4 h; however, large-scale outcome studies are needed to confirm this evidence.

Available only for authorised users

Afshin A, Forouzanfar M, Reitsma, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27. https://doi.org/10.1056/NEJMoa1614362

Rippe J, Crossley S, Ringer R. Obesity as a chronic disease. J Am Diet Assoc. 1998;98(10):S9–15. https://doi.org/10.1016/S0002-8223(98)00704-4.CrossRefPubMed

Eichinger S. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008;168(15):1678. https://doi.org/10.1001/archinte.168.15.1678.CrossRefPubMed

Pierpont Y, Dinh T, Salas R, et al. Obesity and surgical wound healing: a current review. ISRN Obesity. 2014;2014:1–13. https://doi.org/10.1155/2014/638936.CrossRef

Byrne T. Complications of surgery for obesity. Surg Clin North Am. 2001;81(5):1181–93. https://doi.org/10.1016/S0039-6109(05)70190-0.CrossRefPubMed

Lynch R, Ranney D, Shijie C, Lee D, Samala N, Englesbe M. Obesity, surgical site infection, and outcome following renal transplantation. Ann Surg. 2009;250(6):1014–20. https://doi.org/10.1097/SLA.0b013e3181b4ee9a.CrossRefPubMed

Fry D. The economic costs of surgical site infection. Surg Infect. 2002;3(s1):s37–43. https://doi.org/10.1089/sur.2002.3.s1-37.CrossRef

Cheymol G. Effects of obesity on pharmacokinetics. Clin Pharmacokinet. 2000;39(3):215–31. https://doi.org/10.2165/00003088-200039030-00004.CrossRefPubMed

Eleveld D, Proost J, Absalom A, Struys M. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet. 2011;50(11):751–3. https://doi.org/10.2165/11594080-000000000-00000.CrossRefPubMed

10.

Bratzler D, Dellinger E, Olsen K, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect. 2013;14(1):73–156. https://doi.org/10.1089/sur.2013.9999.CrossRef

11.

Joint Formulary Committee. [cited 28 October 2021] British National Formulary (online) London: BMJ Group and Pharmaceutical Press. http://www.medicinescomplete.com

12.

Principles of surgical antibiotic prophylaxis - therapeutic guidelines [Internet]. www.tg.org.au. 2019. [cited October 2021] Available from: https://www.tg.org.au

13.

PRISMA [Internet]. PRISMA. [cited 29 October 2021]. Available from: http://www.prisma-statement.org

14.

Munn Z, Barker T, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2019;18(10):2127–33. https://doi.org/10.11124/JBISRIR-D-19-00099.CrossRef

15.

Roberts J, Kirkpatrick C, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother. 2010;66(2):227–31. https://doi.org/10.1093/jac/dkq449.CrossRefPubMed

16.

Ho V, Nicolau D, Dakin G, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. Surg Infect. 2012;13(1):33–7. https://doi.org/10.1089/sur.2010.097.CrossRef

17.

Swank M, Wing D, Nicolau D, McNulty J. Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. Am J Obstet Gynecol. 2015;213(3):415.e1-415.e8. https://doi.org/10.1016/j.ajog.2015.05.030.CrossRef

18.

Ahmadzia H, Patel E, Joshi D, et al. Obstetric surgical site infections: 2 grams compared with 3 grams of cefazolin in morbidly obese women. Obstet Gynecol. 2015;126(4):Un:708-715. https://doi.org/10.1097/AOG.0000000000001064.CrossRef

19.

Peppard W, Eberle D, Kugler N, Mabrey D, Weigelt J. Association between pre-operative cefazolin dose and surgical site infection in obese patients. Surg Infect. 2017;18(4):485–90. https://doi.org/10.1089/sur.2016.182.CrossRef

20.

Hussain Z, Curtain C, Mirkazemi C, Gadd K, Peterson G, Zaidi S. Prophylactic cefazolin dosing and surgical site infections: does the dose matter in obese patients? Obes Surg. 2018;29(1):159–65. https://doi.org/10.1007/s11695-018-3497-0.CrossRefPubMedCentral

21.

Wiegand I, Hilpert K, Hancock R. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3(2):163–75. https://doi.org/10.1038/nprot.2007.521.CrossRefPubMed

22.

Poulin P, Schoenlein K, Theil F. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci. 2001;90(4):436–47. https://doi.org/10.1002/1520-6017(200104)90:4%3c436::AID-JPS1002%3e3.0.CO;2-P.CrossRefPubMed

23.

Young O, Shaik I, Twedt R, et al. Pharmacokinetics of cefazolin prophylaxis in obese gravidae at time of cesarean delivery. Am J Obstet Gynecol. 2015;213(4):541.e1-541.e7. https://doi.org/10.1016/j.ajog.2015.06.034.CrossRef

24.

Maggio L, Nicolau D, DaCosta M, Rouse D, Hughes B. Cefazolin prophylaxis in obese women undergoing cesarean delivery. Obstet Gynecol. 2015;125(5):1205–10. https://doi.org/10.1097/AOG.0000000000000789.CrossRefPubMed

25.

Palma E, Meinhardt N, Stein A, et al. Efficacious cefazolin prophylactic dose for morbidly obese women undergoing bariatric surgery based on evidence from subcutaneous microdialysis and populational pharmacokinetic modeling. Pharm Res. 2018;35(6). https://doi.org/10.1007/s11095-018-2394-5

26.

Stitely M, Sweet M, Slain D, et al. Plasma and tissue cefazolin concentrations in obese patients undergoing cesarean delivery and receiving differing pre-operative doses of drug. Surg Infect. 2013;14(5):455–9. https://doi.org/10.1089/sur.2012.040.CrossRef

27.

Pevzner L, Swank M, Krepel C, Wing D, Chan K, Edmiston C. Effects of maternal obesity on tissue concentrations of prophylactic cefazolin during cesarean delivery. Obstet Gynecol. 2011;117(4):877–82. https://doi.org/10.1097/AOG.0b013e31820b95e4.CrossRefPubMed

28.

Groff S, Fallatah W, Yang S, et al. Effect of maternal obesity on maternal-fetal transfer of preoperative cefazolin at cesarean section. J Pediatr Pharmacol Ther. 2017;22(3):227–32. https://doi.org/10.5863/1551-6776-22.3.227.CrossRefPubMedPubMedCentral

29.

Anlicoara R, Ferraz Á, da P Coelho K, et al. Antibiotic prophylaxis in bariatric surgery with continuous infusion of cefazolin: determination of concentration in adipose tissue. Obes Surg. 2014;24(9):1487–91. https://doi.org/10.1007/s11695-014-1231-0.CrossRefPubMed

30.

Brill M, Houwink A, Schmidt S, et al. Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother. 2013;69(3):715–23. https://doi.org/10.1093/jac/dkt444.CrossRefPubMed

31.

Edmiston C Jr, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? Surg. 2004;136(4):738–47. https://doi.org/10.1016/j.surg.2004.06.022.CrossRef

32.

Chen X, Brathwaite C, Barkan A, et al. Optimal cefazolin prophylactic dosing for bariatric surgery: no need for higher doses or intraoperative redosing. Obes Surg. 2016;27(3):626–9. https://doi.org/10.1007/s11695-016-2331-9.CrossRef

33.

van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol. 2011;67(10):985–92. https://doi.org/10.1007/s00228-011-1048-x.CrossRefPubMed

34.

Eley V, Christensen R, Ryan R, et al. Prophylactic cefazolin dosing in women with body mass index >35 kg·m−2 undergoing cesarean delivery: a pharmacokinetic study of plasma and interstitial fluid. Anesth Analg. 2020;131(1):199–207. https://doi.org/10.1213/ANE.0000000000004766.CrossRefPubMed

35.

Grégoire M, Dumont R, Ronchi L, et al. Prophylactic cefazolin concentrations in morbidly obese patients undergoing sleeve gastrectomy: do we achieve targets? I Int J Antimicrob Agents. 2018;52(1):28–34. https://doi.org/10.1016/j.ijantimicag.2018.02.015.CrossRefPubMed

36.

Miller M, Fish D, Barber G, et al. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. J Microbiol, Immun and Infect. 2020;53(2):321–7. https://doi.org/10.1016/j.jmii.2018.07.006.CrossRef

37.

Flynt L, Kenney R, Zervos M, Davis S. The safety and economic impact of cefazolin versus nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections. Infect Dis Ther. 2017;6(2):225–31. https://doi.org/10.1007/s40121-017-0148-z.CrossRefPubMedPubMedCentral

38.

Day T, Read A. Does high-dose antimicrobial chemotherapy prevent the evolution of resistance? PLoS Comput Biol. 2016;12(1):e1004689. https://doi.org/10.1371/journal.pcbi.1004689.CrossRefPubMedPubMedCentral

39.

Raymond B. Five rules for resistance management in the antibiotic apocalypse, a road map for integrated microbial management. Evol Appl. 2019;12(6):1079–91. https://doi.org/10.1111/eva.12808.CrossRefPubMedPubMedCentral

40.

Livermore D. Of stewardship, motherhood and apple pie. Int Jour Antimicrob Ag. 2014;43(4):319–22. https://doi.org/10.1016/j.ijantimicag.2014.01.011.CrossRef

41.

Anderson D, Sexton D. Antimicrobial prophylaxis for prevention of surgical site infection in adults - UpToDate [Internet]. Uptodate.com. 2019 [cited October 2021]. Available from: https://www.uptodate.com/contents/antimicrobial-prophylaxis-for-prevention-of-surgical-site-infection-in-adults

42.

Clinical practice guidelines for antimicrobial prophylaxis in surgery [Internet]. Ashp.org. 2013 [cited 6 October 2021]. Available from: https://www.ashp.org/surgical-guidelines

43.

Cheadle W. Risk factors for surgical site infection. Surg Infect. 2006;7(s1):s7–11. https://doi.org/10.1089/sur.2006.7.s1-7.CrossRef

Title: Prophylactic Cefazolin Dosing in Obesity—a Systematic Review
Authors: Matthew Coates
Alison Shield
Gregory M. Peterson
Zahid Hussain
Publication date: 09-07-2022
Publisher: Springer US
Keywords: Obesity
Obesity
Cefazolin
Published in: Obesity Surgery / Issue 9/2022
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-022-06196-5

Single-Port One Anastomosis Duodenal Switch Revision of a Sleeve gastrectomy: First Description

Sleeve Gastrectomy
Multimedia Article

Pregnancy After Sleeve Gastrectomy: Time Matters?

Obesity
Original Contributions

Does the Selection of the Procedure Impact the Return to Work in Unemployed Patients Undergoing Bariatric Surgery?

Open Access
Obesity
Original Contributions

Comments on “Conversion of One Anastomosis Gastric Bypass to Roux-en-Y Gastric Bypass: Results of a Retrospective Multicenter Study”

Malnutrition
Letter to the Editor

The Roles of Depression and Binge Eating in the Relationship Between Adverse Childhood Experiences (ACEs) and Obesity

Obesity
Original Contributions

Novel Use of Lumen-Apposing Metal Stent in the Management of Gastrojejunal Stricture Perforation During Endoscopic Dilatation

Multimedia Article

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Prophylactic Cefazolin Dosing in Obesity—a Systematic Review

Abstract

Other articles of this Issue 9/2022

Single-Port One Anastomosis Duodenal Switch Revision of a Sleeve gastrectomy: First Description

Pregnancy After Sleeve Gastrectomy: Time Matters?

Does the Selection of the Procedure Impact the Return to Work in Unemployed Patients Undergoing Bariatric Surgery?

Comments on “Conversion of One Anastomosis Gastric Bypass to Roux-en-Y Gastric Bypass: Results of a Retrospective Multicenter Study”

The Roles of Depression and Binge Eating in the Relationship Between Adverse Childhood Experiences (ACEs) and Obesity

Novel Use of Lumen-Apposing Metal Stent in the Management of Gastrojejunal Stricture Perforation During Endoscopic Dilatation

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Please log in to get access to this content